Clinical trials: Metastatic Cervical Carcinoma
Esophageal Squamous Cell Carcinoma
Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Combined With or Without Anti-TIGIT Monoclonal Antibody Ociperlimab (BGB-A1217) in Participants With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma
A study of tislelizumab (BGB-A317) plus ociperlimab versus tislelizumab plus placebo as second-line treatment in participants with programmed cell death protein-ligand 1 (PD-L1) tumor area positivity (TAP) ≥ 10% unresectable…
- Trial name
- AdvanTIG-203 (NCT04732494)
- Testing
- Tislelizumab, Ociperlimab
- Where
- 86 sites in China, France and 4 more
- Volunteers
- 125 people
- Sponsor
- BeiGene
Nasopharyngeal Neoplasms
Anlotinib, Penpulimab and Capecitabine in Recurrent/Metastatic Nasopharyngeal Carcinoma
First-diagnosed metastasis or recurrence/metastasis NPC Patients will be treated with anlotinib, penpulimab and capecitabine.
- Trial name
- ALTER-HN005 (NCT05807880)
- Testing
- The combination treatment of anlotinib, penpulimab and capecitabine.
- Where
- China
- Volunteers
- 59 people
- Sponsor
- Sun Yat-sen University
Metastatic Carcinoma to the Uterine Cervix, Recurrent Carcinoma Cervix
Effectiveness of Chemotherapy in Metastatic or Recurrent Carcinoma Cervix
Experience with substituting carboplatin for cisplatin is limited in advanced and recurrent cervix cancer and there has been no counterpart to GOG 158, which documented therapeutic equivalency of cisplatin/paclitaxel and…
- Conditions
- Metastatic Carcinoma to the Uterine Cervix, Recurrent Carcinoma Cervix, Cervix Carcinoma Recurrent
- Trial name
- NCT02492503
- Testing
- Paclitaxel and carboplatin
- Where
- India
- Volunteers
- 40 people
- Sponsor
- All India Institute of Medical Sciences
Head and Neck Squamous Cell Carcinoma (HNSCC)
Screening Trial of Nivolumab With Image Guided, Stereotactic Body Radiotherapy (SBRT) Versus Nivolumab Alone in Patients With Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)
Nivolumab is an antibody (a type of human protein) that is designed to boost your body's immune system. It does this by allowing immune cells to grow and fight the cancer.
- Trial name
- NCT02684253
- Testing
- Nivolumab, Stereotactic Body Radiation Therapy (SBRT)
- Where
- 6 sites in United States
- Volunteers
- 65 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Head and Neck Squamous Cell Carcinoma
AK104 and Low-dose Radiation in Recurrent/Metastatic HNSCC After Failure of First-line Systemic Therapy
Currently, there is a lack of high-quality clinical evidence for subsequent treatment options for recurrent/metastatic head and neck squamous cell carcinoma (HNSCC) after first-line treatment, especially for subsequent treatment…
- Trial name
- NCT06494995
- Testing
- Cadonilimab, Low-dose radiotherapy, SBRT
- Where
- China
- Volunteers
- 52 people
- Sponsor
- Fudan University
Recurrent Cervical Carcinoma, Metastatic Cervical Carcinoma
Tislelizumab and Radiotherapy for Recurrent Cervical Cancer
This study is a prospective, multicenter, phase II clinical trial to evaluate the efficacy and safety of albumin-bound paclitaxel plus bevacizumab for platinum-resistant recurrent epithelial ovarian cancer.
- Conditions
- Recurrent Cervical Carcinoma, Metastatic Cervical Carcinoma, Persistent Cervical Carcinoma, Radiotherapy
- Trial name
- NCT05310383
- Testing
- Tislelizumab plus radiotherapy
- Where
- China
- Volunteers
- 58 people
- Sponsor
- Lei Li
Advanced or Metastatic Solid Tumor, Pancreatic Ductal Adenocarcinoma
AB122 Platform Study
This is a phase 1, non-randomized open-label, multicenter platform study designed to evaluate the tolerability and safety of AB122 in patients with malignancies specified in each cohort.
- Conditions
- Advanced or Metastatic Solid Tumor, Pancreatic Ductal Adenocarcinoma, Colorectal Cancer, Non-small Cell Lung Cancer
- Trial name
- NCT04999761
- Testing
- AB122, TAS-116, TAS-120
- Where
- 9 sites in Japan
- Volunteers
- 917 people
- Sponsor
- Taiho Pharmaceutical Co., Ltd.
Papillary Thyroid Carcinoma
Multimodal Deep Learning for Lymph Node Metastasis in Thyroid Cancer
Papillary thyroid carcinoma (PTC) is the most common endocrine malignancy in clinical practice, accounting for approximately 85% of all thyroid malignancies.
- Trial name
- NCT07299318
- Testing
- not intervention
- Where
- China
- Volunteers
- 3,200 people
- Sponsor
- West China Hospital
Thyroid Neoplasms, Poorly Differentiated and Undifferentiated Thyroid Cancer
CUDC-907 Treatment in People With Metastatic and Locally Advanced Thyroid Cancer
Background: The thyroid is a gland at the base of the throat. Thyroid cancer is a disease that people get when abnormal cells begin to grow in this gland.
- Conditions
- Thyroid Neoplasms, Poorly Differentiated and Undifferentiated Thyroid Cancer, Differentiated Thyroid Cancer
- Trial name
- NCT03002623
- Testing
- CUDC-907
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- National Cancer Institute (NCI)
Laryngeal Cancer, Hypopharyngeal Cancer
The Role of MMPs in the CXCL12-Induced Invasion of Laryngeal and Hypopharyngeal Squamous Cell Carcinoma
Investigate the role of MMPs in the CXCL12-induced invasion of laryngeal and hypopharyngeal squamous cell carcinoma
- Trial name
- NCT00302562
- Where
- Taiwan
- Volunteers
- 100 people
- Sponsor
- National Taiwan University Hospital
Metastatic Head and Neck Carcinoma, Paranasal Sinus Squamous Cell Carcinoma
Pembrolizumab & Cabozantinib in Patients With Head and Neck Squamous Cell Cancer
This phase II trial studies how well pembrolizumab and cabozantinib in treating patients with head and neck squamous cell cancer that has come back or spread to other places in the body and cannot be removed by surgery.
- Conditions
- Metastatic Head and Neck Carcinoma, Paranasal Sinus Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma, Recurrent Hypopharyngeal Squamous Cell Carcinoma
- Trial name
- NCT03468218
- Testing
- Cabozantinib, Pembrolizumab
- Where
- 2 sites in United States
- Volunteers
- 36 people
- Sponsor
- Emory University
Head and Neck Cancer
Everolimus and Docetaxel in Treating Patients With Recurrent, Locally Advanced, or Metastatic Head and Neck Cancer
RATIONALE: Everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Trial name
- DORA (NCT01313390)
- Testing
- docetaxel, everolimus, laboratory biomarker analysis
- Where
- United Kingdom
- Volunteers
- 4 people
- Sponsor
- University College, London
Solid Tumor, Non Small Cell Lung Cancer
A Study Evaluating AB248 Alone or in Combination With Pembrolizumab in Adult Patients With Solid Tumors
This is a phase I, First-in-Human (FIH), open-label study to evaluate the safety, tolerability, pharmacokinetic (PK) profile, and preliminary efficacy of AB248 as monotherapy OR in combination with pembrolizumab in adult…
- Conditions
- Solid Tumor, Non Small Cell Lung Cancer, Melanoma, Squamous Cell Carcinoma of Head and Neck
- Trial name
- NCT05653882
- Testing
- etakafusp alfa (AB248), pembrolizumab
- Where
- 20 sites in United States
- Volunteers
- 552 people
- Sponsor
- Asher Biotherapeutics, Inc.
Esophageal Cancer, Gastric Cancer
Selinexor in Combination With Irinotecan in Adenocarcinoma of Stomach and Distal Esophagus
The main purpose of this study is to see whether the combination of selinexor (KPT-330) and irinotecan can help people with esophageal or stomach cancer.
- Trial name
- NCT02283359
- Testing
- Selinexor, Irinotecan
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma
Atezolizumab and Bevacizumab in Treating Patients With Recurrent, Persistent, or Metastatic Cervical Cancer
This phase II trial studies how well atezolizumab and bevacizumab work in treating patients with cervical cancer that has come back, remains despite treatment, or has spread to other places in the body.
- Conditions
- Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Cervical Squamous Cell Carcinoma, Not Otherwise Specified, Recurrent Cervical Carcinoma
- Trial name
- NCT02921269
- Testing
- Atezolizumab, Bevacizumab, Laboratory Biomarker Analysis
- Where
- 22 sites in United States
- Volunteers
- 11 people
- Sponsor
- National Cancer Institute (NCI)
Head and Neck Cancer, Head and Neck Cancer Squamous Cell Carcinoma
Surufatinib Combined with Envolizumab As Second-line Treatment for Recurrent/Metastatic HNSCC
This study is a prospective,open-label,single-arm clinical trial to evaluate the efficacy and safety of s Surufatinib combined with envolizumab as second-line treatment of recurrent/metastatic head and neck squamous cell…
- Trial name
- HNSCC (NCT06876844)
- Testing
- combination of Surufatinib and Envolizumab
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Metastatic Nasopharyngeal Carcinoma, Metastatic Nasopharyngeal Keratinizing Squamous Cell Carcinoma
Testing the Addition of an Anti-cancer Immune Therapy Drug (Nivolumab) to the Usual Chemotherapy Treatment (Cisplatin or Carboplatin With Gemcitabine) for Recurrent or Metastatic Nasopharyngeal Cancer
This phase III trial compares the effect of adding nivolumab to the usual chemotherapy (cisplatin or carboplatin with gemcitabine) versus standard chemotherapy alone in treating patients with nasopharyngeal cancer that has come…
- Conditions
- Metastatic Nasopharyngeal Carcinoma, Metastatic Nasopharyngeal Keratinizing Squamous Cell Carcinoma, Metastatic Nasopharyngeal Nonkeratinizing Carcinoma, Metastatic Nasopharyngeal Undifferentiated Carcinoma
- Trial name
- NCT04458909
- Testing
- Carboplatin, Cisplatin, Gemcitabine
- Where
- 325 sites in United States, Canada and 2 more
- Volunteers
- 15 people
- Sponsor
- National Cancer Institute (NCI)
Metastatic Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma
Durvalumab, Tremelimumab and Hypofractionated Radiation Therapy in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
This phase I/II trial studies the side effects of durvalumab, tremelimumab and hypofractionated radiation therapy in treating patients with head and neck squamous cell carcinoma that has come back (recurrent) or that has spread…
- Trial name
- NCT03522584
- Testing
- Durvalumab, Laboratory Biomarker Analysis, Stereotactic Body Radiation Therapy
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- University of Washington
Cervical Cancer, Endometrial Cancer
A Study of BL-B01D1 + Pembrolizumab ± Bevacizumab in Patients With Recurrent or Metastatic Cervical Cancer and Endometrial Cancer
This Phase II study is a clinical trial to evaluate the efficacy and safety of BL-B01D1 + pembrolizumab dual therapy with or without bevacizumab (BL-B01D1 + pembrolizumab ± bevacizumab) in patients with recurrent or metastatic…
- Trial name
- NCT07054567
- Testing
- BL-B01D1, Pembrolizumab, Bevacizumab
- Where
- China
- Volunteers
- 96 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Locally Advanced or Metastatic Solid Tumours
A Study to Evaluate Safety and Efficacy of Multiple Dosing With VB10.NEO and Bempegaldesleukin (NKTR-214) Immunotherapy in Patients With Locally Advanced or Metastatic Cancer
This open labelled first in human dose phase 1/2a study is designed to evaluate safety, feasibility and efficacy of multiple dosing with individualised VB10.NEO and bempegaldesleukin (NKTR-214) immunotherapy in patients with…
- Trial name
- DIRECT-01 (NCT03548467)
- Testing
- VB10.NEO, Bempegaldesleukin
- Where
- 6 sites in Germany
- Volunteers
- 41 people
- Sponsor
- Nykode Therapeutics ASA